Research antibodies have long been used to advance HIV/Aids research, however researchers at the California Institute of Technology have recently published a study [PMID: 22033520] developing a new antibody that may someday be used clinically to neutralize HIV. Beginning with a naturally occurring antibody (NIH45-46) purified from HIV positive patients, the researchers modified the antibody using a technique called structure-based rational design. The resulting antibody (NIH45-46G54W) showed some promising new characteristics, including improved specificity and binding against the host receptor (CD4) for many HIV subtypes. This binding neutralizes the HIV by effectively blocking access to the receptor and therefore stopping the proliferation of the virus.
The Caltech research team hopes that their new antibody will eventually lead to clinical treatments using antibodies to block HIV. One of the authors, PJ Borkman, explained, “the results uncover the structural underpinnings of anti-HIV antibody breadth and potency, offer a new view of neutralization by CD4-binding site anti-HIV antibodies, and establish principles that may enable the creation of a new group of HIV therapeutics.”
Novus remains committed to accelerating HIV research as a top supplier of antibodies to infectious viruses, bacteria, & parasites, and we are continually expanding our selection of research antibodies for the many HIV subtypes.